Combination antigene therapy targeting c-myc and c-erbB(2) in the ovarian cancer COC(1) cell line

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Antigene therapy shows promise for ovarian cancer but faces limitations with single-target approaches.
• Targeting oncogenes like c-erbB(2) and c-myc is a key strategy in cancer research.

Purpose of the Study:

• To investigate the in vitro efficacy of combination antigene therapy using liposomal antisense phosphorothioate oligodeoxynucleotides (LF-c-erbB(2)/c-myc AS-ODNs) in human ovarian cancer cells.
• To compare the effects of combined versus single-target antigene therapy on ovarian cancer cell proliferation and gene expression.

Main Methods:

• Human ovarian cancer COC(1) cells were treated with single LF-c-erbB(2) AS-ODNs, single LF-c-myc AS-ODNs, or combination LF-c-erbB(2)/c-myc AS-ODNs.
• Cell proliferation was assessed using MTT assay and clonal cultures.
• Gene expression of c-erbB(2) and c-myc was measured by RT-PCR, and morphologic changes were observed via electron microscopy.

Main Results:

• Single antigene therapies targeting c-erbB(2) or c-myc inhibited COC(1) cell growth by approximately 61.9% and 64.5%, respectively.
• Combination therapy demonstrated a higher inhibitory rate of 82.6% and simultaneously suppressed both c-erbB(2) and c-myc expression.
• Combination antigene therapy also induced apoptosis in COC(1) cells.

Conclusions:

• Combination antigene therapy targeting c-erbB(2) and c-myc effectively inhibits ovarian cancer cell proliferation and reduces target gene expression.
• The combined approach shows significantly greater efficacy compared to individual antigene therapies.
• This study supports combination antigene therapy as a potent strategy for ovarian cancer.